Back

Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases

- 09 January 2023 - 1 mins read

PARIS, FRANCE & BOSTON, U.S., 09 January 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) and Albireo (Nasdaq: ALBO) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases. The anticipated acquisition will enrich Ipsen’s Rare Disease portfolio and pipeline.

Related Press Releases

IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2023
20 June 2023 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2023
Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021
16 June 2023 6 mins read

Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021
Ipsen delivers strong sales growth for the first nine months and improves its full-year guidance
16 June 2023 4 mins read

Ipsen delivers strong sales growth for the first nine months and improves its full-year guidance
Correction: Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
14 June 2023 9 mins read

Correction: Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
14 June 2023 9 mins read

Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome
13 June 2023 8 mins read

U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome
IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2023
13 June 2023 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2023
Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
12 June 2023 11 mins read

Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
12 June 2023 11 mins read

Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
12 June 2023 11 mins read

Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023